Navigation Links
Know your enemy
Date:4/25/2014

rain when Parkinson's disease occurs and develops is absolutely necessary, not only for the prevention and treatment of symptoms, but also for possibly developing a cure one day.

However, getting to know the enemy is no easy task when it comes to understanding Parkinson's disease. The more we find out, the more complex the image becomes.

We already know that the disease as well as other neurological disorders arises because some protein structures in the body start clumping together. They stack themselves on top of each other and gradually form what are known as fibrils long, thin needle-shaped structures. From a biochemical point of view, this is quite a boring process because the protein structures simply pile themselves on top of each other and in principle can continue to do so forever.

It is far more interesting to look at the intermediate stages leading up to the aggregation. It turns out here that when the proteins form fibrils, a kind of intermediate aggregation process also takes place to form oligomers, which consist of a small number of protein molecules that clump together. It is presumably the oligomers that kill the nerve cells and cause the symptoms of Parkinson's disease. So oligomers are the enemy we want to control.

Ground-breaking new knowledge about the enemy

In their two studies, the researchers from Aarhus University, the University of Southern Denmark and the University of Cambridge provide the most well-documented description of oligomers to date. Until now, the general perception was that oligomers were precursors of the fibrils. As it turns out, however, it is rather the antagonists or competitors of the fibrils that are the precursors, and these are capable of slowing down the formation of fibrils.

The researchers discovered that there are different kinds of oligomers. If we look at the size, there are two types that are quite intimately connected. A somewhat small oligomer that
'/>"/>

Contact: Daniel Otzen
dao@inano.au.dk
45-20-72-52-38
Aarhus University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Newly identified small-RNA pathway defends genome against the enemy within
2. How safe is the enemy of a citrus-threatening pest?
3. Influenza study: Meet virus new enemy
4. Lack of energy an enemy to antibiotic-resistant microbes
5. The hungry caterpillar: Beware your enemys enemys enemy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... of American Societies for Experimental Biology (FASEB) is once ... together to prevent sequestration, the automatic across-the-board budget cuts ... 1st. "These automatic spending cuts will stop science advances ... jobs," said FASEB President, Judith S. Bond, PhD. , ...
... MRI and Honorary Lecturer in Cardiovascular Medicine at The University ... the only location in the UK where the trial is ... test manufacturer, to take part in the trial as he ... heart attacks. The other trial sites are in Australia, ...
... open for the Joint Annual Meeting of the American Dairy ... meeting will take place in Indianapolis, IN from July 8 ... feature 35 symposia on topics such as animal genetics, food ... workshops, including a hands-on media training workshop on July 12. ...
Cached Biology News:Manchester patients take part in pioneering heart attack blood test trial 2
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... , July 28, 2015 ... company utilizing its proprietary plant-based rhCollagen technology for ... has been appointed Senior Director of Business Development, ... http://photos.prnewswire.com/prnh/20150728/246955 ) , Ms. ... marketing, regulatory and business strategy. Prior to joining ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... state of the Biophotonics industry.The report provides a basic overview of the industry ... provided for the international markets including development trends, competitive landscape analysis, and key ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® ... Monday. The venture will bring the world’s most efficient gas dissolution technology to ... and technologies to both the industrial and municipal markets. With offices located in ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3BlueInGreen Brings Water Treatment Technology to Florida 2
... IDM Pharma (Nasdaq:,IDMI) today announced that Jeffrey W. ... Medical Officer and Senior Vice President,of Research and Development. ... report to President and CEO Timothy P. Walbert. ... experience to,IDM Pharma and will lead the regulatory and ...
... NanoLogix, Inc. (OTC:,NNLX) is pleased to announce that ... Director of Intellectual Property. In addition, we wish ... the rapid detection of,Anthrax utilizing the NanoLogix BioNanoChannel(TM) ... experience as an intellectual property,counsel in a wide ...
... Drug Royalty LP 2 (DRC) announced,today the ... worldwide,royalty interest in PEG-INTRON for $92.5M. DRC will ... certain royalty recognition levels be met.,PEG-INTRON (peginterferon alpha-2b), ... is marketed worldwide by Schering-Plough Corporation (SGP). ...
Cached Biology Technology:IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 2NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 3Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2
Sheep Serum US Origin...
Human PDGF, CF...
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: